114 related articles for article (PubMed ID: 19572414)
21. Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier.
Bihorel S; Camenisch G; Gross G; Lemaire M; Scherrmann JM
Drug Metab Dispos; 2006 Dec; 34(12):1945-9. PubMed ID: 16936068
[TBL] [Abstract][Full Text] [Related]
22. Increasing tumor uptake of anticancer drugs with imatinib.
Pietras K
Semin Oncol; 2004 Apr; 31(2 Suppl 6):18-23. PubMed ID: 15176000
[TBL] [Abstract][Full Text] [Related]
23. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
[TBL] [Abstract][Full Text] [Related]
24. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
[TBL] [Abstract][Full Text] [Related]
25. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
[TBL] [Abstract][Full Text] [Related]
27. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.
Bilgi N; Bell K; Ananthakrishnan AN; Atallah E
Ann Pharmacother; 2010 May; 44(5):926-8. PubMed ID: 20332334
[TBL] [Abstract][Full Text] [Related]
28. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
Chu TS; Chen JS; Lopez JP; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):979-84. PubMed ID: 18794444
[TBL] [Abstract][Full Text] [Related]
29. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules.
Franssen EJ; Jansen RW; Vaalburg M; Meijer DK
Biochem Pharmacol; 1993 Mar; 45(6):1215-26. PubMed ID: 8466542
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
Steinert DM; McAuliffe JC; Trent JC
Expert Opin Pharmacother; 2005 Jan; 6(1):105-13. PubMed ID: 15709888
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate and its potential implications for gynecologic cancers.
Dushkin H; Schilder RJ
Curr Treat Options Oncol; 2005 Mar; 6(2):115-20. PubMed ID: 15717993
[TBL] [Abstract][Full Text] [Related]
32. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
Manley PW; Blasco F; Mestan J; Aichholz R
Bioorg Med Chem; 2013 Jun; 21(11):3231-9. PubMed ID: 23611771
[TBL] [Abstract][Full Text] [Related]
33. Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS.
Iqbal Z; Elliott M; Watson DG; Holyoake T; Jørgensen H
Pak J Pharm Sci; 2011 Jul; 24(3):285-91. PubMed ID: 21715261
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma.
Thao LQ; Lee C; Kim B; Lee S; Kim TH; Kim JO; Lee ES; Oh KT; Choi HG; Yoo SD; Youn YS
Colloids Surf B Biointerfaces; 2017 Apr; 152():183-191. PubMed ID: 28110040
[TBL] [Abstract][Full Text] [Related]
35. Development of a specific and sensitive enzyme-linked immunosorbent assay for the quantification of imatinib.
Saita T; Shin M; Fujito H
Biol Pharm Bull; 2013; 36(12):1964-8. PubMed ID: 24292055
[TBL] [Abstract][Full Text] [Related]
36. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers.
Marull M; Rochat B
J Mass Spectrom; 2006 Mar; 41(3):390-404. PubMed ID: 16470567
[TBL] [Abstract][Full Text] [Related]
37. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
Judson I; Ma P; Peng B; Verweij J; Racine A; di Paola ED; van Glabbeke M; Dimitrijevic S; Scurr M; Dumez H; van Oosterom A
Cancer Chemother Pharmacol; 2005 Apr; 55(4):379-386. PubMed ID: 15592836
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro.
Wang L; Wang Z; Xia MM; Wang YY; Wang HY; Hu GX
Can J Physiol Pharmacol; 2014 Nov; 92(11):961-4. PubMed ID: 25365188
[TBL] [Abstract][Full Text] [Related]
39. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
40. Imatinib-ULS-lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases.
Dolman ME; van Dorenmalen KM; Pieters EH; Lacombe M; Pato J; Storm G; Hennink WE; Kok RJ
J Control Release; 2012 Feb; 157(3):461-8. PubMed ID: 21911014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
